BeiGene Ltd.
688235.SHG
| Exchange: | SHG |
| Currency | Renminbi |
| Fiscal Year End: | December |
| Sector: | Healthcare |
| Industry: | Biotechnology |
| Gic Sector: | Health Care |
| Gic Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| Gic Industry: | Biotechnology |
| Gic Sub Industry: | Biotechnology |
| Description: | Bei Gene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. Bei Gene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands. |
| Address: | 94 Solaris Avenue, Camana Bay, Cayman Islands, KY1-1108 |
| Website: | https://www.beigene.com |
| Full Time Employees: | 10000 |
| Updated On: | 2024-11-02 |
Highlights
| Market Capitalization: | 162729885696 |
| Market Capitalization Mln: | 162729.88 |
| EBITDA: | -795990016 |
| Wall Street Target Price: | 185.94 |
| Book Value: | 31.73 |
| Earnings Share: | -2.7 |
| EPS Estimate Current Year: | -3.9 |
| EPS Estimate Next Year: | -1.4 |
| Most Recent Quarter: | 2024-06-30 |
| Profit Margin: | -0.16 |
| Operating Margin TTM: | -0.11 |
| Return On Assets TTM: | -0.09 |
| Return On Equity TTM: | -0.14 |
| Revenue TTM: | 3096535040 |
| Revenue Per Share TTM: | 29.65 |
| Quarterly Revenue Growth YOY: | 0.56 |
| Gross Profit TTM: | -511062000 |
| Diluted Eps TTM: | -2.7 |
Valuation
| Forward PE: | 1666.66 |
| Price Sales TTM: | 52.63 |
| Price Book MRQ: | 9.71 |
| Enterprise Value: | 152006604400 |
| Enterprise Value Revenue: | 6.89 |
| Enterprise Value Ebitda: | -86.18 |
Shares
| Shares Outstanding: | 115055000 |
| Shares Float: | 744894312 |
| Percent Insiders: | 4.16 |
| Percent Institutions: | 32.71 |
Technicals
| Beta: | 0.62 |
| 52 Week High: | 207.98 |
| 52 Week Low: | 98.5 |
| 50 Day MA: | 160.63 |
| 200 Day MA: | 134.88 |
Earnings
| Report Date: | 2025-05-06 |
| Date: | 2025-03-31 |
| Before After Market: | After Market |
| Currency: | USD |
| Eps Estimate: | -1.56 |
| Report Date: | 2025-02-24 |
| Date: | 2024-12-31 |
| Before After Market: | After Market |
| Currency: | USD |
| Report Date: | 2024-11-12 |
| Date: | 2024-09-30 |
| Before After Market: | After Market |
| Currency: | USD |
| Report Date: | 2024-08-07 |
| Date: | 2024-06-30 |
| Before After Market: | After Market |
| Currency: | USD |
| Eps Actual: | -8.33 |
| Eps Estimate: | -0.91 |
| Eps Difference: | -7.42 |
| Surprise Percent: | -815.38 |
| Report Date: | 2024-02-26 |
| Date: | 2023-12-31 |
| Before After Market: | After Market |
| Currency: | USD |
| Eps Actual: | -1.95 |
| Eps Estimate: | -0.82 |
| Eps Difference: | -1.13 |
| Surprise Percent: | -137.80 |
| Report Date: | 2023-11-10 |
| Date: | 2023-09-30 |
| Before After Market: | Before Market |
| Currency: | USD |
| Eps Actual: | 1.09 |
| Eps Estimate: | -1.88 |
| Eps Difference: | 2.97 |
| Surprise Percent: | 157.97 |
| Report Date: | 2023-08-02 |
| Date: | 2023-06-30 |
| Before After Market: | After Market |
| Currency: | USD |
| Eps Actual: | -1.96 |
| Eps Estimate: | -1.8 |
| Eps Difference: | -0.16 |
| Surprise Percent: | -8.88 |
| Report Date: | 2023-05-04 |
| Date: | 2023-03-31 |
| Before After Market: | After Market |
| Currency: | USD |
| Eps Actual: | -1.81 |
| Eps Estimate: | -1.77 |
| Eps Difference: | -0.04 |
| Surprise Percent: | -2.25 |
| Report Date: | 2023-02-27 |
| Date: | 2022-12-31 |
| Before After Market: | After Market |
| Currency: | USD |
| Eps Actual: | -2.38 |
| Eps Estimate: | -0.94 |
| Eps Difference: | -1.44 |
| Surprise Percent: | -153.19 |
| Report Date: | 2022-11-09 |
| Date: | 2022-09-30 |
| Before After Market: | After Market |
| Currency: | USD |
| Eps Actual: | -2.81 |
| Eps Estimate: | -2.79 |
| Eps Difference: | -0.02 |
| Surprise Percent: | -0.71 |
| Report Date: | 2022-08-04 |
| Date: | 2022-06-30 |
| Before After Market: | After Market |
| Currency: | USD |
| Eps Actual: | -2.84 |
| Eps Estimate: | -2.2 |
| Eps Difference: | -0.64 |
| Surprise Percent: | -29.09 |
| Report Date: | 2022-05-05 |
| Date: | 2022-03-31 |
| Before After Market: | After Market |
| Currency: | USD |
| Eps Actual: | -2.15 |
| Eps Estimate: | -1.89 |
| Eps Difference: | -0.26 |
| Surprise Percent: | -13.75 |
| Report Date: | 2022-02-25 |
| Date: | 2021-12-31 |
| Before After Market: | After Market |
| Currency: | USD |
| Eps Actual: | -3.18 |
| Eps Estimate: | -2.52 |
| Eps Difference: | -0.66 |
| Surprise Percent: | -26.19 |
| Date: | 2025-12-31 |
| Period: | +1y |
| Growth: | 0.64 |
| Earnings Estimate Avg: | -1.40 |
| Earnings Estimate Low: | -2.55 |
| Earnings Estimate High: | -0.51 |
| Earnings Estimate Year Ago Eps: | -3.90 |
| Earnings Estimate Number Of Analysts: | 6.00 |
| Earnings Estimate Growth: | 0.64 |
| Revenue Estimate Avg: | 29291000000.00 |
| Revenue Estimate Low: | 26090400000.00 |
| Revenue Estimate High: | 34325000000.00 |
| Revenue Estimate Number Of Analysts: | 7.00 |
| Revenue Estimate Growth: | 0.29 |
| Eps Trend Current: | -1.40 |
| Eps Trend7days Ago: | -1.40 |
| Eps Trend30days Ago: | -1.40 |
| Eps Trend60days Ago: | -1.40 |
| Eps Trend90days Ago: | -2.69 |
| Date: | 2024-12-31 |
| Growth: | 0.15 |
| Earnings Estimate Avg: | -3.90 |
| Earnings Estimate Low: | -6.42 |
| Earnings Estimate High: | -2.05 |
| Earnings Estimate Year Ago Eps: | -4.60 |
| Earnings Estimate Number Of Analysts: | 7.00 |
| Earnings Estimate Growth: | 0.15 |
| Revenue Estimate Avg: | 22682900000.00 |
| Revenue Estimate Low: | 21228500000.00 |
| Revenue Estimate High: | 24017000000.00 |
| Revenue Estimate Number Of Analysts: | 7.00 |
| Revenue Estimate Growth: | 0.30 |
| Eps Trend Current: | -3.90 |
| Eps Trend7days Ago: | -3.90 |
| Eps Trend30days Ago: | -3.90 |
| Eps Trend60days Ago: | -3.93 |
| Eps Trend90days Ago: | -4.78 |
| Date: | 2024-06-30 |
| Period: | +1q |
| Growth: | 0.53 |
| Earnings Estimate Avg: | -0.91 |
| Earnings Estimate Low: | -0.91 |
| Earnings Estimate High: | -0.91 |
| Earnings Estimate Year Ago Eps: | -1.96 |
| Earnings Estimate Number Of Analysts: | 1.00 |
| Earnings Estimate Growth: | 0.53 |
| Revenue Estimate Avg: | 5202860000.00 |
| Revenue Estimate Low: | 5202860000.00 |
| Revenue Estimate High: | 5202860000.00 |
| Revenue Estimate Number Of Analysts: | 1.00 |
| Revenue Estimate Growth: | 0.61 |
| Eps Trend Current: | -0.91 |
| Eps Trend7days Ago: | -0.91 |
| Eps Trend30days Ago: | -0.91 |
| Eps Trend60days Ago: | -0.91 |
| Eps Trend90days Ago: | -1.00 |
| Date: | 2024-03-31 |
| Growth: | 0.13 |
| Earnings Estimate Year Ago Eps: | -1.81 |
| Earnings Estimate Growth: | 0.13 |
| Revenue Estimate Low: | 4512370000.00 |
| Revenue Estimate High: | 4512370000.00 |
| Revenue Estimate Number Of Analysts: | 1.00 |
| Revenue Estimate Growth: | 0.47 |
| Eps Trend7days Ago: | -1.56 |
| Eps Trend30days Ago: | -1.56 |
| Eps Trend60days Ago: | -1.56 |
| Eps Trend90days Ago: | -1.56 |
| Date: | 2023-12-31 |
| Growth: | 0.49 |
| Earnings Estimate Avg: | -5.16 |
| Earnings Estimate Low: | -7.19 |
| Earnings Estimate High: | -3.36 |
| Earnings Estimate Year Ago Eps: | -10.18 |
| Earnings Estimate Number Of Analysts: | 7.00 |
| Earnings Estimate Growth: | 0.49 |
| Revenue Estimate Avg: | 17201800000.00 |
| Revenue Estimate Low: | 15210000000.00 |
| Revenue Estimate High: | 18427300000.00 |
| Revenue Estimate Number Of Analysts: | 7.00 |
| Revenue Estimate Growth: | 0.79 |
| Eps Trend Current: | -5.16 |
| Eps Trend7days Ago: | -5.16 |
| Eps Trend30days Ago: | -5.15 |
| Eps Trend60days Ago: | -5.42 |
| Eps Trend90days Ago: | -5.45 |
| Date: | 2023-09-30 |
| Earnings Estimate Avg: | -1.93 |
| Earnings Estimate Low: | -1.93 |
| Earnings Estimate High: | -1.93 |
| Earnings Estimate Number Of Analysts: | 1.00 |
| Revenue Estimate Avg: | 3948750000.00 |
| Revenue Estimate Low: | 3948750000.00 |
| Revenue Estimate High: | 3948750000.00 |
| Revenue Estimate Number Of Analysts: | 1.00 |
| Eps Trend Current: | -1.93 |
| Eps Trend7days Ago: | -1.93 |
| Eps Trend30days Ago: | -1.93 |
| Eps Trend60days Ago: | -1.49 |
| Eps Trend90days Ago: | -1.84 |
| Date: | 2023-06-30 |
| Earnings Estimate Avg: | -1.80 |
| Earnings Estimate Low: | -1.80 |
| Earnings Estimate High: | -1.80 |
| Earnings Estimate Number Of Analysts: | 1.00 |
| Revenue Estimate Avg: | 3224050000.00 |
| Revenue Estimate Low: | 3224050000.00 |
| Revenue Estimate High: | 3224050000.00 |
| Revenue Estimate Number Of Analysts: | 1.00 |
| Eps Trend Current: | -1.80 |
| Eps Trend7days Ago: | -1.80 |
| Eps Trend30days Ago: | -1.84 |
| Eps Trend60days Ago: | -1.84 |
| Eps Trend90days Ago: | -1.76 |
| Eps Revisions Up Last30days: | 1.00 |
| Date: | 2024-09-30 |
| Eps Actual: | -8.3 |
| Date: | 2023-12-31 |
| Eps Actual: | -4.6 |
| Date: | 2022-12-31 |
| Eps Actual: | -10.1 |
| Date: | 2021-12-31 |
| Eps Actual: | -3.1 |